Viking Therapeutics

Oppenheimer raises the price target for Viking Therapeutics to $120 and rates the probability of success for the dual GLP-1/GIP agonist VK2735 as high at 90%. VK2735 showed in clinical data up to 97% maintenance of weight loss with reduced dosing intervals. Viking is therefore focusing on the rapidly growing market for obesity therapies. » Więcej na finanzen.net

Viking Therapeutics' shares jumped 35.7% after phase‑1 data on VK2735 were presented, with investors hoping for opportunities in the growing obesity market. Study results show flexible dosing options, sustained weight loss through week 33 and an unremarkable safety profile. Morgan Stanley reaffirms a buy rating with a fair value of $95, Jefferies and Oppenheimer see price targets of $101 and $120 respectively, and the average target is similar to Morgan Stanley's. After the price surge the market capitalization is just under $4.8 billion; high volatility and risks remain. » Więcej na deraktionaer.de

Viking Therapeutics reported in a maintenance study that VK2735 preserved up to 97% of prior weight loss with biweekly dosing and up to 90% with monthly dosing, compared with 61% for placebo. Gastrointestinal side effects in the maintenance phase were comparable to placebo, and the company is also investigating oral maintenance doses. The stock rose sharply and analysts see considerable upside, with a median price target of around $90. Risks remain, as Viking still faces important clinical and regulatory milestones and the market is dominated by Eli Lilly and Novo Nordisk. » Więcej na finanzen.net

Viking Therapeutics has appointed Dorothy Gemmell to its board of directors with immediate effect. Gemmell brings more than 25 years of experience in healthcare, digital health and commercialization, having held leadership roles at GoodRx, Capsule and Havas Life. The company says the appointment will bolster its commercialization capabilities as it advances the launch of the GLP‑1/GIP agonist VK2735; other programs include VK3019, VK2809 and VK0214. » Więcej na de.investing.com

Viking Therapeutics is developing VK2735, a dual GLP‑1/GIP candidate in both injectable and oral formulations that showed mid‑teens weight loss at 13 weeks in phase 2 trials. The company is running a phase 1 maintenance study with various dosing regimens, with subcutaneous maintenance data expected in Q3 2026 and phase 3 readouts for injectable and oral forms slated from mid‑late 2027 through 2029. Risks include strong competition from established GLP‑1 players and tolerability concerns in the phase 2 oral trial, but successful maintenance or phase 3 data could make Viking an acquisition target. » Więcej na finance.yahoo.com